Eosinophilic Esophagitis (EoE), often referred to as “asthma of the esophagus”, is a chronic allergic/immune condition, which tends to reflect many similar clinical and pathophysiologic characteristics as with asthma. It is characterized by the inflammation of esophagus, and hence, termed as an atopic inflammatory disease of the esophagus.
EoE is marked by the presence of Eosinophil, a type of white blood cell, which is typically present throughout the lining of the esophagus (gastrointestinal tract). The production and accumulation of eosinophils may be caused by many factors, such as immune hypersensitivity responses to particular foods or environmental proteins (allergens) in some affected individuals. The symptoms of eosinophilic esophagitis are variable, especially in people of different ages.
Common symptoms include difficulty in swallowing (dysphagia); food getting stuck in the throat (impaction); nausea; vomiting; poor growth; weight loss; stomach pain; poor appetite; and malnutrition.
DelveInsight’s “Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Eosinophilic Esophagitis, historical and forecasted epidemiology as well as the Eosinophilic Esophagitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Eosinophilic Esophagitis market report provides current treatment practices, emerging drugs, Eosinophilic Esophagitis market share of the individual therapies, current and forecasted Eosinophilic Esophagitis market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Eosinophilic Esophagitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Key highlights of Eosinophilic Esophagitis Market
-
The total prevalent population of Eosinophilic Esophagitis in the 7 major markets were found to be around 456,614 cases in 2017.
-
DelveInsight also estimates higher prevalence of Eosinophilic Esophagitis in the United States with 194,996 in 2017, followed by EU5 and Japan
-
Among the European countries, Germany had the highest prevalent population of Eosinophilic Esophagitis with 54,240 cases, followed by France, which had the prevalent population of 45,162 in 2017. On the other hand, Italy had the lowest prevalent population of 41,819 in 2017
-
Based on DelveInsight analysis, it has been concluded that approximately 15.90% of total US prevalent population of Eosinophilic Esophagitis was the childhood group (i.e., ≤18 years age), accounting for 31,004 cases, while around 84.1% of the total were adults (i.e., >18 years), accounting for 163,991 patients in the year 2017
Request for sample pages:
https://delveinsight.com/sample-request/eosinophilic-esophagitis-market
Eosinophilic Esophagitis Market Outlook
The Eosinophilic Esophagitis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Eosinophilic Esophagitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Eosinophilic Esophagitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
According to DelveInsight, Global burden of Eosinophilic Esophagitis (EoE) has increased over the years. Among the 7 major markets, the United States has reported having maximum prevalent cases of EoE. Though the prevalence of EoE is high across the US, but the condition is often misdiagnosed as other associated diseases such as gastro-esophageal reflux disease (GERD) or Proton-pump inhibitor responsive eosinophilic esophagitis (PPI-REE), ultimately leading to lower treatable pool (when compared to the total prevalent population of the disease) that contributes to the market size of EoE.
Eosinophilic Esophagitis Epidemiology
The Eosinophilic Esophagitis epidemiology division provide insights about historical and current Eosinophilic Esophagitis patient pool and forecasted trend for every seven major countries.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
According to DelveInsight analysis, Prevalence of Eosinophilic Esophagitis is higher among men than women.
Eosinophilic Esophagitis Emerging and Marketed Drugs
Drug chapter segment of the Eosinophilic Esophagitis report encloses the detailed analysis of Eosinophilic Esophagitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Eosinophilic Esophagitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The dynamics of Eosinophilic Esophagitis market (EoE) is anticipated to change during the forecast period, owing to the expected launch of emerging therapies during the forecast period of 2019-2030. Some of the key players in Eosinophilic Esophagitis market include-
-
Dr. FalkPharma
-
Regeneron Pharmaceuticals, Inc. /Sanofi
-
Adare Pharmaceuticals
-
Shire
Table of content:
1. Key Insights
2. Executive Summary of Eosinophilic Esophagitis
3. Competitive Intelligence Analysis for Eosinophilic Esophagitis
4. Eosinophilic Esophagitis Market Overview at a Glance
5. Eosinophilic Esophagitis Disease Background and Overview
6. Eosinophilic Esophagitis Patient Journey
7. Eosinophilic Esophagitis Epidemiology and Patient Population
8. Eosinophilic Esophagitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Eosinophilic Esophagitis Unmet Needs
10. Key Endpoints of Eosinophilic Esophagitis Treatment
11. Eosinophilic Esophagitis Marketed Products
12. Eosinophilic Esophagitis Emerging Therapies
13. Eosinophilic Esophagitis Seven Major Market Analysis
14. Eosinophilic Esophagitis Attribute analysis
15. Eosinophilic Esophagitis Market Outlook
16. Access and Reimbursement Overview
17. KOL Views on Eosinophilic Esophagitis
18. Eosinophilic Esophagitis Market Drivers
19. Eosinophilic Esophagitis Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/